Literature DB >> 11777927

Activation of signal transducer and activator of transcription 1 (STAT1) is not sufficient for the induction of STAT1-dependent genes in endothelial cells. Comparison of interferon-gamma and oncostatin M.

Keyvan Mahboubi1, Jordan S Pober.   

Abstract

We compared human endothelial cell (EC) responses to interferon-gamma (IFN gamma) and oncostatin M (OnM), cytokines that utilize Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling. Both cytokines cause phosphorylation of Tyr residue 701 and Ser residue 727 of STAT1, as shown by immunoblotting. Both activate DNA binding of STAT1 homodimers, shown by electrophoretic mobility shift assay. However, only IFN gamma increases expression of three STAT1-dependent gene products examined, namely transporter associated with antigen processing-1 (TAP1), interferon regulatory factor-1 (IRF1), and class I major histocompatibility complex (MHC) protein, as demonstrated by immunoblotting. Only IFN gamma increases TAP1 transcription assessed by reporter gene assay. OnM pretreatment or co-treatment does not inhibit IFN gamma responses. Interestingly, IFN gamma activation of STAT1 is considerably more long-lived than that produced by OnM. To determine whether duration is functionally significant, we transduced EC with a chimeric receptor containing extracellular domains of platelet-derived growth factor receptor beta and intracellular regions of gp130, the signaling subunit of the OnM receptor, mutated to prevent binding of the tyrosine phosphatase SHP-2. Addition of platelet-derived growth factor to such transduced cells produces STAT1 activation that is comparable in magnitude and duration to that caused by IFN gamma, but still fails to induce TAP1, IRF1, or class I MHC molecules. OnM also activates STAT1 but not transcription of STAT1-dependent genes in HepG2 cells. Transient transfection of HepG2 cells with a STAT-defective mouse IFN gamma receptor failed to complement the OnM STAT signal. We conclude that STAT1 activation is necessary but not sufficient for induction of transcription of IFN gamma-responsive genes. However, signals provided by IFN gamma other than STAT1 activation cannot be provided in trans to complement the response to OnM.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777927     DOI: 10.1074/jbc.M107542200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Signal transduction by human herpesvirus 8 viral interleukin-6 (vIL-6) is modulated by the nonsignaling gp80 subunit of the IL-6 receptor complex and is distinct from signaling induced by human IL-6.

Authors:  Fang Hu; John Nicholas
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

2.  Interleukin-27 acts on hepatic stellate cells and induces signal transducer and activator of transcription 1-dependent responses.

Authors:  Caroline Schoenherr; Ralf Weiskirchen; Serge Haan
Journal:  Cell Commun Signal       Date:  2010-08-19       Impact factor: 5.712

3.  Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain.

Authors:  Iwona Sadzak; Melanie Schiff; Irene Gattermeier; Reingard Glinitzer; Ines Sauer; Armin Saalmüller; Edward Yang; Barbara Schaljo; Pavel Kovarik
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

4.  Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor α (TNFα) and interferon α (IFNα).

Authors:  Xiwen Cheng; Yu Liu; Hao Chu; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2012-05-15       Impact factor: 5.157

5.  Mutational switch of an IL-6 response to an interferon-gamma-like response.

Authors:  Ana P Costa-Pereira; Silvia Tininini; Birgit Strobl; Tonino Alonzi; Joerg F Schlaak; Hayaatun Is'harc; Ida Gesualdo; Sally J Newman; Ian M Kerr; Valeria Poli
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.